In a study assessing the use of the oral IDH2 inhibitor enasidenib to treat AML, what was the histological improvement in the enasidenib cohort versus the conventional care regimens (CCR) cohort?
In a study assessing the use of the oral IDH2 inhibitor enasidenib to treat AML, what was the histological improvement in the enasidenib cohort versus the conventional care regimens (CCR) cohort?